ProQR Therapeutics (PRQR) Operating Leases (2021 - 2025)
Historic Operating Leases for ProQR Therapeutics (PRQR) over the last 4 years, with Q4 2024 value amounting to $11.8 million.
- ProQR Therapeutics' Operating Leases fell 2051.31% to $11.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was $11.8 million, marking a year-over-year decrease of 2051.31%. This contributed to the annual value of $12.0 million for FY2024, which is 1992.08% down from last year.
- Latest data reveals that ProQR Therapeutics reported Operating Leases of $11.8 million as of Q4 2024, which was down 2051.31% from $14.9 million recorded in Q4 2023.
- In the past 5 years, ProQR Therapeutics' Operating Leases registered a high of $16.9 million during Q4 2021, and its lowest value of $11.8 million during Q4 2024.
- For the 4-year period, ProQR Therapeutics' Operating Leases averaged around $14.4 million, with its median value being $14.5 million (2023).
- Per our database at Business Quant, ProQR Therapeutics' Operating Leases soared by 557.33% in 2023 and then crashed by 2051.31% in 2024.
- Quarter analysis of 4 years shows ProQR Therapeutics' Operating Leases stood at $16.9 million in 2021, then dropped by 16.47% to $14.1 million in 2022, then increased by 5.57% to $14.9 million in 2023, then dropped by 20.51% to $11.8 million in 2024.
- Its Operating Leases was $11.8 million in Q4 2024, compared to $14.9 million in Q4 2023 and $14.1 million in Q4 2022.